Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
- Intrahepatic cholangiocarcinoma (iCCA)
- Extrahepatic cholangiocarcinomas:
- (a)
- perihilar cholangiocarcinoma (pCCA; formerly called Klatskin tumor)—located in the vicinity of the hepatic hilum;
- (b)
- distal cholangiocarcinoma (dCCA)—located in the distal section of the common bile duct.
Author Contributions
Conflicts of Interest
References
- Mauro, E.; Ferrer-Fàbrega, J.; Sauri, T.; Soler, A.; Cobo, A.; Burrel, M.; Iserte, G.; Forner, A. New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy. Cancers 2023, 15, 1244. [Google Scholar] [CrossRef]
- Bath, N.M.; Pawlik, T.M. Narrative review: Current management and novel targeted therapies in intrahepatic cholangiocarcinoma. Chin. Clin. Oncol. 2023, 12, 5. [Google Scholar] [CrossRef]
- Ruff, S.M.; Shannon, A.H.; Pawlik, T.M. Advances in Targeted Immunotherapy for Hepatobiliary Cancers. Int. J. Mol. Sci. 2022, 23, 13961. [Google Scholar] [CrossRef]
- Kelley, R.K.; Bridgewater, J.; Gores, G.J.; Zhu, A.X. Systemic therapies for intrahepatic cholangiocarcinoma. J. Hepatol. 2020, 72, 353–363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moris, D.; Palta, M.; Kim, C.; Allen, P.J.; Morse, M.A.; Lidsky, M.E. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J. Clin. 2023, 73, 198–222. [Google Scholar] [CrossRef] [PubMed]
- Bridgewater, J.; Galle, P.R.; Khan, S.A.; Llovet, J.M.; Park, J.; Patel, T.; Pawlik, T.M.; Gores, G.J. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 2014, 60, 1268–1289. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Esmail, A.; Mazzaferro, V.; Abdelrahim, M. Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision. Cancers 2022, 14, 5074. [Google Scholar] [CrossRef]
- Brandi, G.; Rizzo, A. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? Int. J. Mol. Sci. 2022, 23, 10869. [Google Scholar] [CrossRef]
- Huang, P.; Huang, X.; Zhou, Y.; Yang, G.; Sun, Q.; Shi, G.; Chen, Y. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. Can. J. Gastroenterol. Hepatol. 2022, 2022, 9680933. [Google Scholar] [CrossRef] [PubMed]
- Kendre, G.; Murugesan, K.; Brummer, T.; Segatto, O.; Saborowski, A.; Vogel, A. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J. Hepatol. 2023, 78, 614–626. [Google Scholar] [CrossRef] [PubMed]
- Lidsky, M.E.; Wang, Z.; Lu, M.; Liu, A.; Hsu, S.D.; McCall, S.J.; Sheng, Z.; Granek, J.A.; Owzar, K.; Anderson, K.S.; et al. Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies. NPJ Precis. Oncol. 2022, 6, 75. [Google Scholar] [CrossRef] [PubMed]
- Shi, G.; Huang, X.; Wen, T.; Song, T.; Kuang, M.; Mou, H.; Bao, L.; Zhao, H.; Zhao, H.; Feng, X.; et al. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study. Cancer Med. 2023, 12, 4137–4146. [Google Scholar] [CrossRef] [PubMed]
- Abou-Alfa, G.K.; Bibeau, K.; Schultz, N.; Yaqubie, A.; Millang, B.; Ren, H.; Féliz, L. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Target. Oncol. 2022, 17, 517–527. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wasilewicz, M.P.; Becht, R. Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to? Medicina 2023, 59, 729. https://doi.org/10.3390/medicina59040729
Wasilewicz MP, Becht R. Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to? Medicina. 2023; 59(4):729. https://doi.org/10.3390/medicina59040729
Chicago/Turabian StyleWasilewicz, Michał P., and Rafał Becht. 2023. "Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?" Medicina 59, no. 4: 729. https://doi.org/10.3390/medicina59040729